Weijun Wang1, Haiping He2,3, Nagore I Marín-Ramos1, Shan Zeng2,3, Steven D Swenson1, Hee-Yeon Cho1, Jie Fu3, Paul M Beringer4,5, Josh Neman1,6,7, Ligang Chen2,3, Axel H Schönthal8, Thomas C Chen1,6,7. 1. Department of Neurological Surgery, University of Southern California, Los Angeles, California, USA. 2. Department of Neurosurgery, Luzhou, China. 3. Department of Neurology Affiliated Hospital of Southwest Medical University, Luzhou, China. 4. Department of Clinical Pharmacy, Los Angeles, California, USA. 5. School of Pharmacy, University of Southern California, Los Angeles, California, USA. 6. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA. 7. Keck School of Medicine, University of Southern California, Los Angeles, California, USA. 8. Department of Microbiology and Immunology, University of Southern California, Los Angeles, California, USA.
Abstract
BACKGROUND: The antitumor efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as humanized monoclonal antibody trastuzumab (Herceptin®, Roche), in patients with breast-to-brain cancer metastasis is hindered by the low permeability of the blood-brain barrier (BBB). NEO100 is a high-purity version of the natural monoterpene perillyl alcohol, produced under current good manufacturing practice (cGMP) regulations, that was shown previously to reversibly open the BBB in rodent models. Here we investigated whether NEO100 could enable brain entry of trastuzumab to achieve greater therapeutic activity. METHODS: An in vitro BBB, consisting of human astrocytes and brain endothelial cells, was used to determine trastuzumab penetration in the presence or absence of NEO100. For in vivo studies, we administered intravenous (IV) trastuzumab or the trastuzumab-drug conjugate ado-trastuzumab emtansine (T-DM1; Kadcyla®, Roche), to mouse models harboring intracranial HER2+ breast cancer, with or without BBB opening via IA NEO100. Brain and tumor tissues were examined for the presence of trastuzumab and infiltration of immune cells. Therapeutic impact was evaluated based on overall survival. RESULTS: NEO100 greatly increased trastuzumab penetration across an in vitro BBB. In vivo, IA NEO100-mediated BBB opening resulted in brain tumor-selective accumulation of trastuzumab, without detectable presence in normal brain tissue, along with increased presence of immune cell populations. IV delivery of trastuzumab or T-DM1 achieved significantly greater overall survival of tumor-bearing mice when combined with IA NEO100. CONCLUSION: IA NEO100 facilitates brain tumor entry of trastuzumab and T-DM1 and significantly enhances their therapeutic efficacy, along with increased antibody-dependent immune cell recruitment.
BACKGROUND: The antitumor efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as humanized monoclonal antibody trastuzumab (Herceptin®, Roche), in patients with breast-to-brain cancer metastasis is hindered by the low permeability of the blood-brain barrier (BBB). NEO100 is a high-purity version of the natural monoterpene perillyl alcohol, produced under current good manufacturing practice (cGMP) regulations, that was shown previously to reversibly open the BBB in rodent models. Here we investigated whether NEO100 could enable brain entry of trastuzumab to achieve greater therapeutic activity. METHODS: An in vitro BBB, consisting of human astrocytes and brain endothelial cells, was used to determine trastuzumab penetration in the presence or absence of NEO100. For in vivo studies, we administered intravenous (IV) trastuzumab or the trastuzumab-drug conjugate ado-trastuzumab emtansine (T-DM1; Kadcyla®, Roche), to mouse models harboring intracranial HER2+ breast cancer, with or without BBB opening via IA NEO100. Brain and tumor tissues were examined for the presence of trastuzumab and infiltration of immune cells. Therapeutic impact was evaluated based on overall survival. RESULTS: NEO100 greatly increased trastuzumab penetration across an in vitro BBB. In vivo, IA NEO100-mediated BBB opening resulted in brain tumor-selective accumulation of trastuzumab, without detectable presence in normal brain tissue, along with increased presence of immune cell populations. IV delivery of trastuzumab or T-DM1 achieved significantly greater overall survival of tumor-bearing mice when combined with IA NEO100. CONCLUSION: IA NEO100 facilitates brain tumor entry of trastuzumab and T-DM1 and significantly enhances their therapeutic efficacy, along with increased antibody-dependent immune cell recruitment.
Authors: S Dawood; N T Ueno; V Valero; E Andreopoulou; L Hsu; J Lara; W Woodward; T A Buchholz; G N Hortobagyi; M Cristofanilli Journal: Ann Oncol Date: 2010-05-03 Impact factor: 32.976
Authors: Nagore I Marín-Ramos; Moisés Balabasquer; Francisco J Ortega-Nogales; Iván R Torrecillas; Ana Gil-Ordóñez; Beatriz Marcos-Ramiro; Pedro Aguilar-Garrido; Ian Cushman; Antonio Romero; Francisco J Medrano; Consuelo Gajate; Faustino Mollinedo; Mark R Philips; Mercedes Campillo; Miguel Gallardo; Mar Martín-Fontecha; María L López-Rodríguez; Silvia Ortega-Gutiérrez Journal: J Med Chem Date: 2019-06-19 Impact factor: 7.446
Authors: Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Joanne E Mortimer; Laura Kruper; Mary Cianfrocca; Sayeh Lavasani; Sariah Liu; Niki Tank-Patel; Mina Sedrak; Wade Smith; Daphne Stewart; James Waisman; Christina Yeon; Tina Wang; Yuan Yuan Journal: J Clin Med Date: 2020-06-24 Impact factor: 4.241
Authors: Tiziana Triulzi; Viola Regondi; Loris De Cecco; Maria Rosa Cappelletti; Martina Di Modica; Biagio Paolini; Pier Luigi Lollini; Serena Di Cosimo; Lucia Sfondrini; Daniele Generali; Elda Tagliabue Journal: Br J Cancer Date: 2018-11-27 Impact factor: 7.640
Authors: E Laakmann; I Witzel; T Neunhöffer; T-W Park-Simon; R Weide; K Riecke; A Polasik; M Schmidt; J Puppe; C Mundhenke; K Lübbe; T Hesse; M Thill; D-M Zahm; C Denkert; T Fehm; V Nekljudova; J Rey; S Loibl; V Müller Journal: ESMO Open Date: 2022-05-30